Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Guidance Emphasizes Randomized, Blinded Trials For PMAs

This article was originally published in The Gray Sheet

Executive Summary

Clinical studies in support of pre-market approval applications should ideally be randomized and blinded, FDA maintains in recent guidance.
Advertisement

Related Content

FDA Articulates Design Principles For Pivotal Trials In Final Guidance
A Long, Strange Trip: 510(k) Reform At One Year
Regulatory News In Brief
FDA Hopes To Finalize Most 510(k) Reform Guidances In 2012
Risk-Benefit Guidance Aims To Improve Pre-Market Review Predictability
Risk-Benefit Guidance Aims To Improve Pre-Market Review Predictability
Risk-Benefit Guidance Aims To Improve Pre-Market Review Predictability
Research Backlash: Does FDA Have A PMA Problem?
Research Backlash: Does FDA Have A PMA Problem?
Two Reviews Question Quality Of Cardiac PMA Trials

Topics

Advertisement
UsernamePublicRestriction

Register

MT030457

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel